Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Cancer Research UK Phase I study to determine the maximum tolerated dose of the oral Src/ABL inhibitor AZD0424, and to identify tolerable and effective AZD0424 combination regimens for the treatment of advanced solid tumours.

Trial Profile

A Cancer Research UK Phase I study to determine the maximum tolerated dose of the oral Src/ABL inhibitor AZD0424, and to identify tolerable and effective AZD0424 combination regimens for the treatment of advanced solid tumours.

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 17 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AZD 0424 (Primary) ; Antineoplastics
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 13 Feb 2018 Results published in the British Journal of Cancer.
    • 25 Jul 2016 Status changed from active, no longer recruiting to discontinued as single agent phase completed, and there is insufficient supportive preclinical data to proceed with combination phase
    • 29 Mar 2016 Status changed from suspended to active, no longer recruiting, according to ClinicalTrials.gov record.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top